NCT01503242View on ClinicalTrials.gov

90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 9, 2012

Primary Completion Date

June 6, 2017

Study Completion Date

December 6, 2019

Conditions
Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Interventions
PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo allogeneic peripheral blood stem cell transplantation

DRUG

Cyclosporine

Given PO

DRUG

Fludarabine Phosphate

Given IV

DRUG

Mycophenolate Mofetil

Given IV or PO

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo allogeneic peripheral blood stem cell transplantation

RADIATION

Total-Body Irradiation

Undergo TBI

RADIATION

Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8

Given IV

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT01503242 - 90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma | Biotech Hunter | Biotech Hunter